Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration

Harnessing the structural plethora of peptides to discover novel therapeutics.
3B Pharmaceuticals GmbH (3BP), a private German biotechnology company today announced a multi-year collaboration in the field of peptide-led drug discovery with Boehringer Ingelheim.

Under the agreement, 3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets nominated by Boehringer Ingelheim. Hit compounds identified will be further optimized and jointly characterized by both companies. 

Dr. Ulrich Reineke, Managing Director of 3BP stated: “We are very pleased to substantially broaden our relationship with Boehringer Ingelheim and confident in adding significant value through our validated peptide hit discovery and medicinal chemistry capabilities.”

Financial terms of the collaboration were not disclosed.

About 3B Pharmaceuticals

3B Pharmaceuticals is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3B Pharmaceuticals has built a technology platform extending from hit identification to early clinical development. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Berlin, Bern and Basel. The company is owned by its founders and management. For more information on 3B Pharmaceuticals, visit 

Media contact
Dr. Jan Michel
Director Finance & Corporate Development
Tel.: +49 (30) 6392-4317  
Fax.: +49 (30) 6392-4316